Moderna mRNA Vaccine Trial: To Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults to Prevent COVID19
Brief description of study
The Moderna mRNA-1273 vaccine is being developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection. The study is designed to primarily evaluate the efficacy, safety, and immunogenicity of mRNA-1273 to prevent COVID-19 for up to 2 years after the second dose of mRNA-1273.
Detailed description of study
- The Cove Study is a Phase 3 study of an experimental vaccine against SARS-CoV-2 called mRNA-1273.
- This study is also known as “mRNA-1273-P301.”
- The study vaccine was developed by ModernaTX, Inc. They are located in Cambridge, Massachusetts. Moderna specializes in developing the use of mRNA technology for vaccines and treatments for a number of diseases.
- The study vaccine is known as an mRNA vaccine.
- The study will enroll about 30,000 people in the US.
- Our site is hoping to recruit widely from racially and ethnically diverse groups that have been impacted in greater numbers during the pandemic.
Please fill out the prescreener questions below to see if you pre-qualify for the study. Meeting initial criteria does not guarantee entry into the trial.
Final eligibility decision is made by the physician and clinical team, after reviewing medical records.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
COVID-19,COVID19,vaccine,
-
Age: Between 18 Years - 100 Years
-
Gender: All
- People with underlying health conditions, such as heart disease, high blood pressure, and diabetes.
- People with a greater chance of exposure at their job.
- People who live or work in elder-care facilities.
- People who work in jails or prisons.
- People from racial and ethnic groups that have been impacted in greater numbers by the epidemic, such as African Americans, Latinx, and Native Americans.
Updated on
04 Jul 2023.
Study ID: 843626